adapting an integrated approach to this problem utilizing, wherever possible, an interdisciplinary concept that includes techniques derived from pharmacology, pathology, toxicology, drug metabolism and various other related disciplines. Such advances have helped to mitigate the frustrations of the biological investigator which were adequately expressed in the 19th century by Roger Bacon who stated, &dquo;the operative and practical scientists which do their work on insensate bodies can multiply their experiments until rid of deficiences and errors but a physician cannot do this because of the nobility of the material with which he works&dquo;. This erudite investigator was somewhat in error on this point, for it was rather common even then for irregular, poorly planned, dangerous, and sometime heroic experiments to be carried out in humans, a practice which was unfortunately continued all the way into the 20th century. In nothing more, such historical events should emphasize to us the importance that modern day biological investigators should place on appropriate utilization of laboratory animals and effective methodology. Experimental animals can be used quite effectively in developing toxicologic data that has practical utility in predicting the relative safety of new chemicals.
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An assessment of the potential hazards of chemical compounds in experimental animals can usually facilitate the adoption of precautionary measures to minimize hazards that might attend human exposure. It should be emphasized, however, that the ideal chemical that provides useful economic or therapeutic effects, and is at the same time absolutely safe for animals and/or man, has not been invented, nor is one likely to be. However, deliberate human exposure should occur only after appropriate testing has been carried out in experimental animals. Scientists who are responsible for the introduction of a new chemical into the environment, or directly into man, are aware that such decisions entail a certain element of risk, and a decision to proceed should be guided by the total relevant experience with a given compound. Developing the data essential for making such judgments requires the coordinated effort of several disciplines. The purpose of this presentation is to highlight some of the considerations involved in this complex area of investigation.
METHODS
As with any area of research, semantic difficulties are often encountered in the field of toxicologic investigation. One of these is the very common use of the term &dquo;safety&dquo;. Absolute safety is, of course, unobtainable. However, the toxicologic profile of a given chemical which has been developed in several different species of animals can provide a basis for a general assessment of relative toxicity or safety. For this purpose, a sequence such as that shown below might be considered.
As indicated there, provision is made for the flow of initial and feedback information from one major area of investigation to another which should eventually provide a basis for establishing the relative safety of a given agent.
Earlier, I emphasized the need for extending our scope of investigative techniques to include a number derived from several related disciplines. A word of caution is in order, however. New techniques should be introduced for routine use only after appropriate trial and validation have shown that they have utility. In accord with this general concept, it is useful to postulate the degree of reliability that might be placed on animal data derived by various available techniques. One such model is shown in Figure 1 , kindly loaned by Dr.
Harold Grice.
Chief Pathology Section, Food and Drug Directorate, Tunney's Pasture, Ottawa, Ontario, Canada.
This model serves to illustrate the wide array of disciplines that are currently needed in safety evaluations, as well as the projected extrapolation of reliability. Clearly, not all of the disciplines or specialties listed there are pertinent to a given investigation. However, the techniques should be available for use when needed.
SELECTION OF ANIMAL MODELS
A primary consideration in pharmacologic pathology is the proper selection of animal models. Consideration should be given to the species (e.g., mammal, fish, bird, insect), the strain or breed of animals, and the specific advantages or disadvantages of each (e.g., size, ease of maintenance, reproductive ability, life span). The natural extension of envestigations in animal models is, of course, to man himself, which is essential in the case of drugs. It should be emphasized, however, that the usefulness of laboratory animal models can be only as great as the predictive value of the data obtained from them.
The extensive use of the rat and dog probably reflects the availability of these species and the considerable background experience we have had with them. Primates occasionally offer certain advantages in special areas such as endocrine and reproductive toxicology. However, the &dquo;ideal species&dquo; that will typically predict either pharmacologic or toxicologic responses for man has not yet been found, nor is one likely to appear during our lifetime. Certain overt pharmacologic effects can, of course, be elicited in appropriate species (e.g., hypertension, diuresis, hypoglycemia, hyperlipidemia). Less predictable and extremely worrisome effects include immunologic responses and certain other low frequency phenomena.
DESIGN OF EXPERIMENTS
Background data derived from classical pharmacologic experiments can be very useful in the initial design of toxicologic protocols. Such data might in clude dose response, primary and/or secondary pharmacologic activities, and an intended or preferred route of-exposure or administration. Frequently, an extension of these data can be obtained from metabolic studies which should be designed to answer questions on the distribution of compounds to organs and subcellular sites, and whether or not the metabolic pattern explains species differences enountered in pharmacologic or toxicologic studies. Major metabolic considerations may include absorption, excretion, distribution, pharmacokinetics, biotransformation, enzyme induction or inhibition, protein binding, displacement from binding sites, interference with absorption, changes in excretion patterns and pharmacogenetic differences. Although complete metabolic data are rarely available in the early stages of toxicologic investigations, available preliminary information on absorption, distribution and excretion can be quite helpful in the initial design of toxicologic protocols. More extensive metabolic data are usually developed during later stages of investigation and can be used retrospectively to examine the consequences of a chemical compound or drug given to different species. For most environmental agents not intended for use in man, extrapolation of animal safety data must of necessity be made at this point, since man will rarely be deliberately exposed to substantial quantities of potentially hazardous agents.
TYPES OF TESTS
The evolution of toxicologic approaches and procedures have been accompanied by efforts to categorize certain of these with respect to magnitude and temporal relationships. For the most part, these categories are ill-defined, but they are rather useful for purposes of discussion.
Acute toxicity: This term ordinarily implies a determination of single lethal doses by one or more routes of administration. Customarily, an estimate of the lethal dose (e.g., LD50, LD100) is a common end result of such experiments. Since death is the end point, little ancillary information is obtained (e.g., effects on target organs, and clinicopathologic evaluation). Dose range-finding (extended acute) toxicity: Ordinarily this procedure involves daily treatment by selected routes of administration for periods of 2-4 weeks. The principle purpose of such studies is to select doses for longer term experiments. In addition, certain information on organ function and clinical response can be obtained. Subacute Toxicity: This term ordinarily designates an experiment designed to run approximately 1-3 months, and will include comprehensive clinicopathologic and histopathologic evaluation. Other types of observations may be made as needed (e.g., histochemical, autoradiographic, endocrinological).
Chronic Toxicity: This term generally indicates experiments designed to run for periods of 6 months or more. In the case of Pharmaceutical agents, the current time period is ordinarily one year in mammals such as dogs, monkeys or rats. In carcinogenicity tests are included the test design will usually stipulate 18 or 24 months for mice and rats, respictively. Special areas (e.g., teratogenicity and mutagenicity): In the past 10-15 years traditional approaches to teratologic studies have become routine and are widely used. Considerable interest in the area of mutagenicity has been generated during the past 3-4 years, particularly in the area of environmental chemicals. These problems, however, are far from resolved and both areas of investigation are undergoing continuous review and evolution.
As mentioned earlier in this presentation, the purpose of this report is to highlight some of the considerations involved in experimentai design in pharmacologic pathology. This is a dynamic area of investigation, and the concepts must be reviewed and occasionally changed in accord with the &dquo;state of the art&dquo;. Flexibility in this regard and a willingness on the part of investigators to modify their concepts as needed are essential to further advnaces in this area of research. The existing knowledge of cellular pathology is mainly derived from observations by light microscopy. Recent advances in electron microscopy have introduced a new pathology, the cell organelle or subcellular pathology in which the structure of altered cell organelles and consequently their altered function can be elucidated. In this respect, electron microscopy has bridged the large gap between morphology and function or, in other words, between light microscopy and biochemistry.
APPLICATION OF ELECTRON
The electron microscope is currently in use as a fundamental tool in the analysis of subcellular changes induced by drugs and chemical agents thus adding a new dimension to the evaluation of drug safety at the ultrastructural level. With the high resolution of the electron microscope, it is now possible to detect early phases of cell injury long before they are visible in the light microscope, or to pinpoint sites of defects in transport mechanisms, or to locate sites of drug actions such as those involved in microsomal biotransformation, drug hydroxylation, detoxification, etc.
As the space available does not permit to review the volumenous studies dealing with this criterion, this presentation will portray only a few illustrations from our recent studies of how the electron microscope has contributed to the safety evaluation of chemicals and therapeutic agents.
During screening tests of CNS-active compounds in rats, it has been found that daily oral administration of one of these compounds at a dose level of 40 mg. per kg of body weight induced peculiar diffuse massive hepatic necrosis within 7 weeks in Charles -River Sprague-Dawley rats of both sexes. Partial hepatectomy enhanced the development of this peculiar type of necrosis (3 weeks instead of 7) while administration of phenobarbital prior treatment delayed the .appearance of necrosis but did not reduce its severity.
When examined electron microscopically, early development of the hepatic lesion appeared within 2 days in the form of dark osmiophilic vesicles scattered around the bile canaliculi of the hepatocytes, Fig. 1 . One week later, these peculiar bodies were converted into lysosomes causing the destruction of liver cells. The smooth endoplasmic reticulum was markedly increased and the Golgi vesicles were unusually dilated. The involvement of these organelles and the transformation of these bodies to lysosomes suggested an impairment of the transport mechanism(s) of the hepatocytes by this compound (1,2).
Fig. 1 : Osmiophilic vesicles in the vicinity of bile canaliculi
In another study, the electron microscope played an important role in clearing a misinterpretation of a phenomenon that has been overlooked when using the light microscope. Oral administration of 2-ethyl-2-phenyl butyramide to dogs produced remarkable yellowish-brown deposits in the hepatocytes and their bile canaliculi. When seen by the light microscope, these deposits closely resembled those commonly encountered in cases of cholestasis, hence the compound was regarded as a cholestatic agent producing bile plugs. Ultrastructural studies of these livers revealed the presence of clusters of filamentous structures randomly located in the hepatocytes, in dilated bile canaliculi and in Kuppfer cells (Fig. 2) . The electron microscopic picture of these deposits differed totally from that of the bile plugs. This lead has directed us to apply histochemical and biochemical tests which finally proved that these deposits were protoporphyrin and that this compound is an outspoken potent porphyria-inducing agent in the canine liver (3,4). 
